Systematic Review of Traumatic Brain Injury Animal Models.

The goals of this chapter are to provide an introduction into the variety of animal models available for studying traumatic brain injury (TBI) and to provide a concise systematic review of the general materials and methods involved in each model. Materials and methods were obtained from a literature search of relevant peer-reviewed articles. Strengths and weaknesses of each animal choice were presented to include relative cost, anatomical and physiological features, and mechanism of injury desired. Further, a variety of homologous, isomorphic/induced, and predictive animal models were defined, described, and compared with respect to their relative ease of use, characteristics, range, adjustability (e.g., amplitude, duration, mass/size, velocity, and pressure), and rough order of magnitude cost. Just as the primary mechanism of action of TBI is limitless, so are the animal models available to study TBI. With such a wide variety of available animals, types of injury models, along with the research needs, there exists no single "gold standard" model of TBI rendering cross-comparison of data extremely difficult. Therefore, this chapter reflects a representative sampling of the TBI animal models available and is not an exhaustive comparison of every possible model and associated parameters. Throughout this chapter, special considerations for animal choice and TBI animal model classification are discussed. Criteria central to choosing appropriate animal models of TBI include ethics, funding, complexity (ease of use, safety, and controlled access requirements), type of model, model characteristics, and range of control (scope).

Kallikrein-related peptidase 6: a biomarker for traumatic brain injury in the rat.

BACKGROUND: Establishment of a traumatic brain injury (TBI)-sensitive biomarker or identification of a key therapeutic agent would significantly improve clinicians' efforts to diagnose and treat TBI, thereby promoting improved outcomes for patients. Numerous studies support the role of kallikrein-6 (Klk6) as a critical component of neuroinflammation and demyelination. This study assesses whether Klk6 is implicated in the secondary mechanisms of TBI and subsequently if serum levels of Klk6 are useable as a biomarker. METHODS: The abundance of Klk6 following controlled cortical impact (CCI) of the medial prefrontal cortex to a depth of either 3.0 mm (severe) or 1.5 mm (moderate) was quantified. Uninjured and rats subjected to craniotomy-only were used as controls. Protein levels were quantified with Western-blotting, enzyme-linked immunosorbent assay and immunohistochemistry. RESULTS: Severe and moderate CCI resulted in significant elevation of Klk6 in the contusion-core (~12-fold-increase, p < 0.0001) and serum (~5-fold-increase, p < 0.01) compared to controls. In all cases, Klk6 elevation was resolved within 72 hours. CONCLUSION: Serum levels of Klk6 are a statistically significant indicator of TBI 24 hours after CCI and thus may be of great utility to clinicians as a biomarker. These data strongly implicate Klk6 as a player in the neuroinflammation processes following CCI, although the specific mechanisms remain to be characterized.